BD Makes Advances in Tissue Regeneration with New Clinical Trial Milestone
In a significant step forward for the field of medical technology, BD (Becton, Dickinson and Company), a global leader in healthcare solutions, has announced that its STANCE clinical trial has successfully reached a crucial phase of patient enrollment. The trial, which focuses on the innovative GalaFLEX LITE™ Scaffold, aims to address major challenges faced in breast revision surgeries, particularly complications arising from capsular contracture. This development comes at a time when it is crucial to enhance safety and efficacy for patients undergoing implant-based breast surgeries.
The STANCE trial has registered 274 patients across 33 active sites in the United States, surpassing 50% of the planned maximum enrollment, which varies between 250 to 530 participants based on adaptive design criteria. This milestone is not just a statistic; it represents the potential revolutionizing of breast revision surgery through advanced clinical technology. Capsular contracture, a condition where the scar tissue surrounding the breast implant hardens excessively, is a frequent complication affecting up to 20% of patients who undergo breast augmentation procedures.
Currently, conventional strategies for treating this complication can lead to recurrence rates as high as 54%, leaving many patients disheartened by the limits of existing solutions. It's in response to such challenges that BD has committed to innovative solutions like the GalaFLEX LITE™ Scaffold. Art Stephen, the Global RD Leader of Surgery at BD, emphasized that the STANCE trial reflects the company’s dedication to enhancing patient care by generating substantial clinical evidence that could support new indications for this product.
The GalaFLEX LITE™ Scaffold is designed to integrate with the anatomical contours of the body, providing vital support throughout the healing process. Constructed from poly-4-hydroxybutyrate (P4HB), this bioabsorbable material has been successfully utilized in various soft tissue procedures, including hernia repairs, for over a decade. The ongoing research aims not only to address capsular contracture in breast revisions but also to enhance overall patient outcomes in plastic surgery.
Dr. Caroline Glicksman, a key figure in the trial and a certified plastic and reconstructive surgeon, pointed out the necessity of this study in furthering patient care and reducing recurrence of capsular contracture. As enrollment progresses smoothly across the trial sites, there is hopeful anticipation for the continued collection of essential clinical data that will ultimately influence new FDA applications for the GalaFLEX LITE™ Scaffold.
This pioneering trial exemplifies BD's broader mission of advancing healthcare through innovative technologies and solutions. With over 60,000 employees globally and a commitment to improving health outcomes and efficiency, BD remains at the forefront of medical technology. The ongoing dedication to research and development in advanced tissue regeneration reflects an understanding of the intricate needs of patients and the medical field alike.
As trials like STANCE develop, the hope is that they will lead not only to improved clinical outcomes but also a significant transformation in how complications associated with breast surgeries are managed. The ultimate goal is to provide patients with not only care but also comfort and confidence in their surgical options. For more details and updates regarding the GalaFLEX LITE™ Scaffold and the ongoing research, interested parties are encouraged to visit BD’s official website.
The STANCE trial has registered 274 patients across 33 active sites in the United States, surpassing 50% of the planned maximum enrollment, which varies between 250 to 530 participants based on adaptive design criteria. This milestone is not just a statistic; it represents the potential revolutionizing of breast revision surgery through advanced clinical technology. Capsular contracture, a condition where the scar tissue surrounding the breast implant hardens excessively, is a frequent complication affecting up to 20% of patients who undergo breast augmentation procedures.
Currently, conventional strategies for treating this complication can lead to recurrence rates as high as 54%, leaving many patients disheartened by the limits of existing solutions. It's in response to such challenges that BD has committed to innovative solutions like the GalaFLEX LITE™ Scaffold. Art Stephen, the Global RD Leader of Surgery at BD, emphasized that the STANCE trial reflects the company’s dedication to enhancing patient care by generating substantial clinical evidence that could support new indications for this product.
The GalaFLEX LITE™ Scaffold is designed to integrate with the anatomical contours of the body, providing vital support throughout the healing process. Constructed from poly-4-hydroxybutyrate (P4HB), this bioabsorbable material has been successfully utilized in various soft tissue procedures, including hernia repairs, for over a decade. The ongoing research aims not only to address capsular contracture in breast revisions but also to enhance overall patient outcomes in plastic surgery.
Dr. Caroline Glicksman, a key figure in the trial and a certified plastic and reconstructive surgeon, pointed out the necessity of this study in furthering patient care and reducing recurrence of capsular contracture. As enrollment progresses smoothly across the trial sites, there is hopeful anticipation for the continued collection of essential clinical data that will ultimately influence new FDA applications for the GalaFLEX LITE™ Scaffold.
This pioneering trial exemplifies BD's broader mission of advancing healthcare through innovative technologies and solutions. With over 60,000 employees globally and a commitment to improving health outcomes and efficiency, BD remains at the forefront of medical technology. The ongoing dedication to research and development in advanced tissue regeneration reflects an understanding of the intricate needs of patients and the medical field alike.
As trials like STANCE develop, the hope is that they will lead not only to improved clinical outcomes but also a significant transformation in how complications associated with breast surgeries are managed. The ultimate goal is to provide patients with not only care but also comfort and confidence in their surgical options. For more details and updates regarding the GalaFLEX LITE™ Scaffold and the ongoing research, interested parties are encouraged to visit BD’s official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.